Maravai LifeSciences Holdings, Inc.
MRVIAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 9, 2026 | UBS | Douglas Schenkel | $8.00(+11%) | $7.19 | StreetInsider |
| May 8, 2026 | Deutsche Bank | $6.00(+33%) | $4.50 | TheFly | |
| Dec 15, 2025 | Wells Fargo | Brandon Couillard | $4.50(+25%) | $3.60 | TheFly |
| Mar 21, 2025 | Stifel Nicolaus | $5.00(+120%) | $2.27 | TheFly | |
| May 9, 2024 | Robert W. Baird | Catherine Schulte | $10.00(+13%) | $8.87 | TheFly |
| Dec 14, 2022 | Deutsche Bank | $25.00(+66%) | $15.03 | Benzinga | |
| Dec 7, 2022 | RBC Capital | $22.00(+76%) | $12.50 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| UBS | maintain | Neutral | Sep 9, 2026 |
| Wells Fargo | maintain | Overweight | Aug 7, 2026 |
| Wells Fargo | maintain | Overweight | May 8, 2026 |
| Wells Fargo | maintain | Overweight | Dec 15, 2025 |
| Craig-Hallum | maintain | Buy | Aug 12, 2025 |
| RBC Capital | maintain | Outperform | Aug 12, 2025 |
| Craig-Hallum | maintain | Buy | May 13, 2025 |
| Baird | maintain | Neutral | May 13, 2025 |
| Morgan Stanley | maintain | Equal Weight | Mar 25, 2025 |
| UBS | maintain | Neutral | Mar 21, 2025 |
| B of A Securities | maintain | Buy | Mar 3, 2025 |
| Baird | downgrade | Outperform →Neutral | Feb 26, 2025 |
| Goldman Sachs | downgrade | Neutral →Sell | Dec 5, 2024 |
| RBC Capital | maintain | Outperform | Nov 8, 2024 |
| Baird | maintain | Outperform | Nov 8, 2024 |
| William Blair | downgrade | Outperform →Market Perform | Nov 8, 2024 |
| Goldman Sachs | maintain | Neutral | Oct 8, 2024 |
| RBC Capital | maintain | Outperform | Aug 16, 2024 |
| Morgan Stanley | downgrade | Overweight →Equal Weight | Aug 13, 2024 |
| Goldman Sachs | maintain | Neutral | Aug 8, 2024 |
| UBS | maintain | Neutral | Aug 8, 2024 |
| Goldman Sachs | maintain | Neutral | Jul 9, 2024 |
| Baird | maintain | Outperform | May 9, 2024 |
| Stifel | maintain | Buy | Feb 23, 2024 |
| RBC Capital | maintain | Outperform | Feb 23, 2024 |
Earnings History
Next report: Feb 24, 2027 · EPS est. $-0.04| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $-0.03 | $-0.06 | $45.9M | $43.6M |
| Aug 6, 2026 | $-0.02 | $-0.04 | $51.4M | $48.7M |
| May 7, 2026 | $0.01 | $-0.05 | $65.8M | $53.0M |
| Feb 25, 2026 | $-0.04 | $-0.07 | $49.9M | $49.0M |
| Nov 6, 2025 | $-0.08 | $-0.06 | $41.6M | $49.1M |
| Aug 11, 2025 | $-0.08 | $-0.06 | $47.4M | $50.1M |
| May 12, 2025 | $-0.08 | $-0.07 | $46.9M | $44.0M |
| Mar 18, 2025 | $-0.06 | $-0.03 | $56.4M | $57.8M |
News
Maravai LifeSciences Holdings, Inc. ( MRVI ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Debra Hart - Senior Director of Investor Relations Bernd Brust - CEO & Director Rajesh Asarpota - EVP & Chief Financial Officer Conference Call Participants Matthew Stanton - Jefferies LLC, Research Division Brendan Smith - TD Cowen, Research Division Justin Bowers - Deutsche Bank AG, Research Division Sean Gardner - UBS Investment Bank, Research Division Jacob Krahenbuhl - Willia…
Maravai LifeSciences NASDAQ: MRVI raised its 2026 revenue and adjusted EBITDA forecasts after reporting third-quarter sales growth of 10%, driven by demand for mRNA products and continued growth at its Cygnus business.
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $45.9 million, Net loss of $(24.0) million, and Adjusted EBITDA of $5.8 million; Full year 2026 revenue guidance range increased to $212.0 million to $.
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter financial and operating results after the market close on Wednesday, November 4, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4849 or 1-203-518-9848 and reference Marav.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) has received an average recommendation of "Hold" from the five ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company.
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5., named "Compositions and Methods for Synthesizing 5'-Capped RNAs." The patent marks TriLink's second granted CleanCap® patent in China within a matter of months, and expands.
Maravai (MRVI) is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, embedding products across the customer lifecycle. Q2 2026 marked a profitability inflection, with gross margins rising to 40.1% and Adjusted EBITDA turning positive, reflecting successful cost realignment and segment-level improvement. TriLink's integrated GMP enzyme facility and ModTail technology strengthen customer stickiness, while Cygnus provides recurring, high-margin biologics safety …
Dimensional Fund Advisors LP boosted its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) by 64.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,418,597 shares of the company's stock after buying an additional 558,050 shares during the
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) shares gapped down before the market opened on Friday. The stock had previously closed at $6.25, but opened at $5.60. Maravai LifeSciences shares last traded at $5.6880, with a volume of 683,238 shares. Key Headlines Impacting Maravai LifeSciences Here are the key news stories impacting